首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1881255

抗體合作與許可協議：2019-2025

Antibody Collaboration and Licensing Deals 2019-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 750+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告全面深入分析了全球領先的生物製藥公司簽署的抗體相關協議，並提供前所未有的資訊管道。

本報告詳細闡述並分析了公司簽署抗體協議的原因和方法。這些協議通常包含多個組成部分，從合作研發開始，最終實現成果的商業化。

本報告涵蓋合作研發、研究和授權協議。

本報告包含自2019年以來公佈的1486項抗體交易的完整清單，其中包括可用的財務條款以及各方披露的實際抗體合作交易的線上記錄連結。此外，在條件允許的情況下，記錄中還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

主要優勢：

了解2019年及以後的合約趨勢
查看抗體領域的合作與授權協議
基準分析：確定交易市場價值
財務條款：預付款、里程碑付款、特許權使用費
依公司名稱（A-Z）、合約類型和治療領域分類的合約目錄
以價值為排名的熱門交易
最活躍的交易撮合者
識別每份合約的資產描述和條款
存取合約文件：深入了解合約結構
盡職調查：評估擬議合約條款是否適合您的合作夥伴
節省數百小時的研究時間

分析合約內容有助於進行以下方面的盡職調查：

合約授予或選擇哪些具體權利？
合約實際授予合作夥伴哪些權利？
授予哪些獨家銷售權？
合約的付款結構是什麼？
銷售和付款將如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
智慧財產權（IPR）將如何處理，所有權歸誰？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和資訊揭露？
如何解決爭議？
合約在什麼情況下可以終止？
如果所有權發生變更，會發生什麼事？
雙方約定的轉授權和分包條款是什麼？
公司通常會包含哪些標準條款？
哪些標準條款會因交易對手和合約類型而異？
根據合約法，該公司要求適用哪一方（法院）的管轄法律？

本報告包含自2019年以來公佈的1486項抗體交易的完整列表，包括可用的財務條款以及指向交易雙方披露的實際抗體合作交易在線記錄的鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了抗體交易的趨勢。

第一章概述了本報告。

第二章概述了自 2019 年以來的抗體交易趨勢。

第三章概述了自 2019 年以來的主要抗體交易，並依交易總額排序。

第四章提供了最活躍的 25 家抗體交易撮合者的完整名單，並附有簡要概述，隨後提供了抗體交易和公開合約文件的完整清單。

第五章對自 2019 年 1 月以來已完成和宣布的、合約文件公開的抗體交易進行了全面深入的回顧。

第六章對自2019年1月以來已達成和公佈的抗體合作協議進行了全面深入的回顧。本章依具體的抗體技術類型進行組織。

報告中還包含大量表格和圖表，展示了自2019年以來抗體交易的趨勢和活動。

此外，我們還提供了一個全面的合約目錄，依公司名稱（依字母順序排列）、合約類型和治療靶點進行分類。每個合約標題都連結到合約記錄的線上版本，並在可用的情況下連結到合約文件，方便用戶根據需要輕鬆存取每個合約文件。

主要優勢

"抗體合作與許可協議報告" 提供讀者以下主要優勢：

了解 2019 年及以後的交易趨勢
瀏覽抗體合作與許可協議
基準分析 - 確定交易市場價值
財務條款 - 預付款、里程碑付款、特許權使用費
依公司（A-Z）、合約類型和治療領域分類的合約目錄
以交易價值排名的熱門交易
最活躍的交易撮合者
識別每筆交易的資產描述和條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
節省數百小時的研究時間。

範圍

本報告 "抗體合作與許可協議" 旨在幫助讀者深入了解全球主要生物製藥公司簽訂的抗體相關協議的趨勢和結構。

本報告涵蓋：

生物製藥產業的抗體交易趨勢
製藥和生物技術公司抗體交易記錄目錄
以價值排名的主要抗體交易
最活躍的抗體許可協議
"抗體合作與許可協議" 提供對現有交易記錄的全面訪問，包括合約文件（如有）。

分析合約內容可協助您對以下內容進行盡職調查：

協議授予或選擇哪些具體權利？
合約實際上賦予合作夥伴哪些權利？
授予了哪些獨家經營權？
交易的付款結構是怎麼樣的？
銷售和付款如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
智慧財產權（IPR）如何處理歸屬於誰？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和資訊揭露？
如何解決爭議？
在什麼情況下可以終止合約？
如果所有權發生變更會發生什麼事？
如何就分授權和分包條款達成協議？
貴公司要求哪些標準條款？
哪些標準條款會因合作夥伴和交易類型而異？
貴公司要求以哪個司法管轄區的法律作為合約的適用法律？

This report contains a comprehensive listing of 1486 antibody deals announced since 2019 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

Trends in antibody dealmaking in the biopharma industry
Directory of antibody deal records covering pharmaceutical and biotechnology
The leading antibody deals by value
Most active antibody licensing dealmakers
Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

2.1. Introduction
2.2. Antibody deals over the years
2.3. Most active antibody dealmakers
2.4. Antibody deals by deal type
2.5. Antibody deals by therapy area
2.6. Antibody deals by industry sector
2.7. Deal terms for antibody deals
- 2.7.1 Antibody deals headline values
- 2.7.2 Antibody deal upfront payments
- 2.7.3 Antibody deal milestone payments
- 2.7.4 Antibody royalty rates